#	Pagina
attuale pagina	/open-h2020/projects/198893/index.html

Opendata, web and dolomites

Tomo-FPS

Tomosynthesis is a low-dose alternate to has CT already transformed Breast Imaging, our vision is to reduce the costs, further enhance sensitivity and reduce dose, and transform portability.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

Tomo-FPS project word cloud

Explore the words cloud of the Tomo-FPS project. It provides you a very rough idea of what is the project "Tomo-FPS" about.

ct transformed parts consistency radically modalities tomosynthesis emission speed subject continues magnetic power accepted potentially safer reduce footprint angle dose visualize move 2d quantify moving device limited levels image screening localise changing disease offerings flat computed innovation resolution tomography objectivity vary objects worldwide biomarkers review radiation breast market 90 ray 5bn adaptix reducing demonstrated unlike giving cheaper true near performing capability planar source world acquisition radiology resonance form dimensions dimension lung majority mri equal 50 weight diagnostic global constitutes 60 healthcare ultrasound imaging closer cancer tissues symptomatic workhorse panel transform fps despite basic circa medical nodules small size progression bone versus 3d

Project "Tomo-FPS" data sheet

The following table provides information about the project.

Coordinator	ADAPTIX LTD Organization address address: BEGBROKE SCIENCE PARK - WOODSTOCK ROAD city: OXFORD postcode: OX5 1PF website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.adaptiximaging.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-10-01 to 2015-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ADAPTIX LTD ADAPTIX LTD Organization address address: BEGBROKE SCIENCE PARK - WOODSTOCK ROAD city: OXFORD postcode: OX5 1PF website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	coordinator	50˙000.00

Map

Project objective

The power of 3D X-ray imaging in healthcare in the form of Computed Tomography (CT) is widely accepted, but despite the widespread availability of CT and Magnetic Resonance Imaging (MRI) it is still the basic 2D planar X-ray that constitutes the majority (circa 60%) of medical imaging studies worldwide. Planar X-ray continues to be the “workhorse of radiology” because of its availability, low cost and small system footprint (compared to MRI and CT); its speed of image acquisition and review (compared to all other modalities); its ability to visualize tissues like bone (unlike MRI and Ultrasound); its low radiation dose (unlike CT); and its consistency and objectivity of image acquisition (unlike Ultrasound).

Tomosynthesis, a method for performing high-resolution limited-angle tomography at low dose levels, has already transformed breast cancer screening and has demonstrated an ability to near-equal CT in identifying lung nodules symptomatic of lung cancer.

Our innovation is a Flat Panel X-ray Source (FPS) that allows tomosynthesis without any moving parts. This will reduce costs and enhance acquisition speed and allows the source to be closer to the subject, reducing power needs and further reducing cost.

Unlike current tomosynthesis devices that move the source in 1 dimension, a system using an FPS could vary emission in 2 dimensions which could enhance depth resolution and the ability to localise objects. This would enhance the ability to quantify features, including biomarkers of disease progression.

Adaptix will transform planar X-ray by giving it true 3D capability, making it safer by reducing dose (versus CT, and potentially versus planar X-ray), making the systems 50% cheaper than existing market offerings and reducing weight and size by 90%. By doing this we will be improving access to the world’s most important medical diagnostic device and radically changing a $5bn global market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TOMO-FPS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TOMO-FPS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination